BA
AVNR

BlackRock Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

BlackRock Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-333,553
Closed -$5.65M – 3750
2014
Q4 		$5.65M Buy
333,553
+236,204
+243% +$3.32M 0.01% 933
2014
Q3 		$1.16M Buy
97,349
+729
+0.8% +$4.98K ﹤0.01% 1357
2014
Q2 		$545K Sell
96,620
-8,144
-8% -$37.5K ﹤0.01% 1963
2014
Q1 		$384K Buy
104,764
+5,760
+6% +$22K ﹤0.01% 2242
2013
Q4 		$333K Buy
99,004
+9,375
+10% +$38.7K ﹤0.01% 2333
2013
Q3 		$379K Buy
89,629
+1,200
+1% +$5.69K ﹤0.01% 2130
2013
Q2 		$407K Buy
+88,429
New +$304K ﹤0.01% 1979

BlackRock Advisors's AVNR Position: Q1 2015 in Review

BlackRock Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 333,553 shares — an estimated $5.65M sold.

BlackRock Advisors first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $5.65M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • BlackRock Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • BlackRock Advisors sold 333,553 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $5.65M.
  • BlackRock Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • BlackRock Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $5.65M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on BlackRock Advisors's 13F filing for Q1 2015, filed 13 May 2015.